ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0036 • ACR Convergence 2024

    Deep Topic Modeling Deconvolves Cell States in Spatial Transcriptomic Profiles of Rheumatoid Arthritis Synovial Tissue

    Preethi Periyakoil1, Melanie Smith2, Meghana Kshirsagar3, Daniel Ramirez4, Edward Dicarlo5, Susan Goodman6, Laura Donlin2 and Christina Leslie7, 1Weill Cornell Medical College, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Microsoft AI for Good, Seattle, 4Hospital for Special Surgery, Cartago, Costa Rica, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 6Hospital for Special Surgery, New York 10025, NY, 7Memorial Sloan Kettering Cancer Center, New York, NY

    Background/Purpose: Recent single-cell RNA sequencing (scRNA-seq) studies of the rheumatoid arthritis (RA) synovium have highlighted the heterogeneity of cell states present during active disease. It…
  • Abstract Number: 0053 • ACR Convergence 2024

    Fasting Reduces an IL-17+/IFNg+ T Helper Cell-inducing Gut Pathobiont in Patients with Rheumatoid Arthritis

    Márcia Pereira1, Katja Stuhlträger2, Natalie Scherff3, Anika Rajput Khokhar4, Sylvio Redanz1, Hebah Ebid5, Bérénice Hansen5, Cédric C. Lacny5, Ulrike Löschberger2, Stefan Bletz6, Jochen G. Schneider7, Paul Wilmes7, Christian S. Kessler4, Andreas Michalsen4, Alexander Mellmann3 and Martin Kriegel1, 1Institute of Musculoskeletal Medicine, University of Münster, Department of Translational Rheumatology and Immunology, Münster, Germany, Münster, Germany, 2Institute of Musculoskeletal Medicine, University of Münster, Department of Translational Rheumatology and Immunology, Münster, Germany, Muenster, Germany, 3Institute of Hygiene, University Hospital Münster, Münster, Germany, Muenster, Germany, 4Institute of Social Medicine, Epidemiology and Health Economics, Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, 54University of Luxembourg, Department of Life Sciences and Medicine (DLSM), 6, Avenue du Swing, L-4367 Belvaux, Luxembourg, Luxemburg, Luxembourg, 6Institute of Hygiene, University Hospital Münster, Germany, Muenster, Germany, 7University of Luxembourg, Department of Life Sciences and Medicine (DLSM), 6, Avenue du Swing, L-4367 Belvaux, Luxembourg, Luxemburg, Luxembourg

    Background/Purpose: The mucosal origins hypothesis suggests rheumatoid arthritis (RA) is triggered at mucosal sites in genetically predisposed hosts1. Animal models support that microbiota‐induced Th17 cells are…
  • Abstract Number: 0131 • ACR Convergence 2024

    Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study

    Carol Hitchon1, Dawn Bowdish2, Gilles Boire3, Paul Fortin4, Louis Flamand5, Vinod Chandran6, Roya M Dayam7, Anne-Claude Gingras8, Catherine Card9, Ines Colmegna10, Maggie Larche2, Gil Kaplan11, Luck Lukusa12, Jennifer Lee12 and Sasha Bernatsky13, and SUCCEED investigative team, 1University of Manitoba, Winnipeg, MB, Canada, 2McMaster University, Hamilton, ON, Canada, 3Retired, Sherbrooke, QC, Canada, 4Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 5Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, 6University of Toronto, Toronto, ON, Canada, 7Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada, 8Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, 9National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada, 10The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 11University of Calgary, Calgary, AB, Canada, 12The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 13Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Given ongoing SARS-CoV-2 circulation, COVID-19 vaccination response in immune-mediated inflammatory disease (IMID) remains a key issue, particularly regarding effects of common immunosuppressives like methotrexate…
  • Abstract Number: 0207 • ACR Convergence 2024

    Investigation of Delays in Cancer Screening in RA

    Rebecca Brooks1, Cassondra Hulshizer2, Andrew C. Hanson3, Vanessa Kronzer1, John Davis1, Elena Myasoedova1 and Cynthia Crowson1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Utica, MN, 3Mayo Clinic, Rochester

    Background/Purpose: Recent studies have shown that RA patients have increased mortality due to cancer. Despite the increased mortality, few studies have investigated the completion of…
  • Abstract Number: 0357 • ACR Convergence 2024

    Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves

    Clifton Bingham1, Emily Molina2, Amy Praestgaard3, Stefano Fiore3 and David Cella4, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins, Baltimore, MD, 3Sanofi, Bridgewater, NJ, 4Northwestern University, Chicago, IL

    Background/Purpose: To evaluate changes over time in fatigue measured by Patient Reported Outcome Measures Information System (PROMIS)-Fatigue scores in rheumatoid arthritis (RA) patients treated with…
  • Abstract Number: 0457 • ACR Convergence 2024

    Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis

    Joshua Baker1, George Reed2, Geoffrey Thiele3, Dimitrios Pappas4, christina Charles-Schoeman5, Monica Guma6, Leslie Harrold7, Jeffrey Curtis8 and Joel Kremer9, 1Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, 2University of Massachusetts Chan Medical School, Worcester, MA, 3University of Nebraska Medical Center, Omaha, NE, 4CorEvitas, New York, NY, 5UCLA Medical Center, Santa Monica, CA, 6UCSD, La Jolla, CA, 7CorEvitas, Northborough, MA, 8University of Alabama at Birmingham, Hoover, AL, 9The Corrona Research Foundation, Delray Beach, FL

    Background/Purpose: While BMI has been associated with response to therapy in several studies in rheumatoid arthritis (RA), it is not a comprehensive measure of the…
  • Abstract Number: 0473 • ACR Convergence 2024

    Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology

    NATALUCCI Francesco1, SOKOLOVA Tatiana2, NZEUSSEU TOUKAP Adrien3, GALANT Christine4, ABOUBAKAR Frank5, BAURAIN Jean-François6, CORNELIS Frank6, BORBATH Yvan7, DUREZ Patrick2 and MERIC de BELLEFON Laurent2, 1Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 3Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, 4Department of Pathological Anatomy, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 5Division of Pneumology, Cliniques Universitaires Saint-Luc, Brussels, Brussels, Belgium, 6Medical Oncology Department, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, 7Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium

    Background/Purpose: The increasing use of Immune Check-Point Inhibitors (ICIs) to treat malignancy focused attention on immune-related adverse events (irAEs). ICIs-induced arthritis is the most common…
  • Abstract Number: 0491 • ACR Convergence 2024

    Small Molecule Metabolites, Potential Disease-specific Biomarkers for Predicting Treatment Response in Rheumatoid Arthritis

    Jiayi Xu1, Yi Zhao2, Chenxi Zhu3, Yi Liu4, Tao Chen1, Rui Sun3, Huifang Hu5, Zhen Zhou1 and Yan Liu1, 1Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Cheng du, China (People's Republic), 2Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic), 3Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), 4Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, 5Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Chengdu, Sichuan, China (People's Republic)

    Background/Purpose: Rheumatoid arthritis (RA) is a complex chronic inflammatory condition primarily affecting joints, presenting a challenge in understanding its causes, varied subtypes, diagnostic indicators, and…
  • Abstract Number: 0507 • ACR Convergence 2024

    Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib

    Runa Kuley1, Bhargavi Duvvuri1, Sabeeha Hasnain2, Ernst Dow3, Alisa Koch4, Richard Higgs4, Venkatesh Krishnan4 and Christian Lood5, 1University of Washington, Seattle, 2Mahindra University, Hyderabad, India, 3Eli Lilly and Co, Indianapolis, IN, 4Eli Lilly, Indianapolis, IN, 5University of Washington, Seattle, WA

    Background/Purpose: Neutrophils play an important role in regulating immune and inflammatory responses in rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce…
  • Abstract Number: 0524 • ACR Convergence 2024

    Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers

    Laura Galindo Domínguez1, Belen Acasuso2, Vanesa Balboa-Barreiro3, Juan Fernández-Tajes2, Juan Cañete4, Benjamin Fernández-Gutiérrez5, Isidoro González-Álvaro6, José L Pablos7, Carmen Bejerano-Herreria8, Maite Silva-Díaz9, Franciso javier De-Toro-Santos2, Natividad Oreiro10 and francisco J Blanco11, 1Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, 2Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, 3Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, 4Hospital Clinic an IDIBAPS, Barcelona, Spain, 53Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, 6University Hospital La Princesa, Madrid, Madrid, Spain, 7Health ministry, Madrid, Madrid, Spain, 8Hospital Universitario Marqués de Valdecilla, Santander, Spain, 9Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 10CHUAC, La Coruna, Galicia, Spain, 11INIBIC-University of A Coruña, A Coruña, Spain

    Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
  • Abstract Number: 0794 • ACR Convergence 2024

    Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup

    Shreena Kamlesh Gandhi1, Sofia Pedro2, Brian Walitt3, Winfried Häuser4, Robert Katz5 and Kaleb Michaud6, 1KU School of Medicine, Wichita, Wichita, KS, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3NIH, Bethesda, MD, 4Klinikum Saarbrücken Germany, Munich, Germany, 5Rush University Medical Center, Chicago, IL, 6University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Disability benefits are crucial for individuals unable to work due to debilitating medical conditions, commonly facilitated through programs like Social Security Disability Insurance (SSD)…
  • Abstract Number: 0873 • ACR Convergence 2024

    Epigenetic Control of Pathogenic CD4 T Cell Polarization During Progression to Rheumatoid Arthritis (RA)

    Ziyuan He1, Pravina Venkatesan1, Adam Savage1, Marla Glass1, Lauren Okada2, Upaasana Krishnan2, Christy Bennett1, Nhung Tran2, Yudong He2, Samir Rachid Zaim1, Padmapriyadarshini Ravisankar2, Jessica Garber2, Palak Genge2, Kevin Lee2, Regina Mettey2, Cole Phalen2, Sugandhika Khosa2, Marie Feser3, Fan Zhang4, David Boyle5, Kristine Kuhn4, Kristen Demoruelle6, Cate Speake7, Jane Buckner8, Ananda Goldrath1, Thomas Bumol9, V. Michael Holers10, Peter Skene1, Gary Firestein11, Xiaojun Li1, Kevin Deane12, Troy Torgerson13 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2Allen Institute for Immunology, Seattle, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado, Aurora, CO, 5UCSD, La Jolla, CA, 6University of Colorado Anschutz Medical Campus, Golden, CO, 7Benaroya Research Institute at Virginia Mason, Seattle, 8Benaroya Research Institute, Seattle, WA, 9Allen Institute for Immunology, San Diego, CA, 10University of Colorado, Denver, CO, 11University of California, San Diego, San Diego, CA, 12University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 13Allen Institute for Immunology, Enumclaw, WA

    Background/Purpose: Multiple T cell subsets, including Th1, Th17 cells, and Tfh/Tph, contribute to rheumatoid arthritis (RA) pathology. Clinical trials have shown efficacy of T cell…
  • Abstract Number: 0939 • ACR Convergence 2024

    A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis

    Hemalatha Nanjaiah, Rakeshchandra Meka, Bodhraj Acharya, Shivaprasad Venkatesha and Kamal Moudgil, University of Maryland School of Medicine, Baltimore, Baltimore, MD

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease of synovial joints, and it affects over 1 per cent of the population worldwide. Uncontrolled or…
  • Abstract Number: 0993 • ACR Convergence 2024

    Pulmonary Complications and Mortality Trends in Rheumatoid Arthritis Patients Aged 65 and Older in the United States: A CDC WONDER Database Analysis

    Muhammad Naveed1, Rabia Iqbal1, Kishan Patel2, Ahila Ali1, Simran Bhimani3, Bazil Azeem4, Yash Deshpande3, Muhammad Omer Rehan1, Faizan Ahmed5, Hussain Haider Shah1 and Nouman Shafique6, 1Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan, 2Riverside Community Hospital, Riverside, CA, 3The Wright Center for graduate medical education, Scranton, PA, 4Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan, 5Ameer-ud-Din Medical College, Lahore, Pakistan, 6AdventHealth Orlando, Orlando, FL

    Background/Purpose: Pulmonary complications in rheumatoid arthritis (RA) are an important cause of mortality among older adults. This study analyzes trends and demographic disparities in mortality…
  • Abstract Number: 1045 • ACR Convergence 2024

    Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

    Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

    Background/Purpose: Rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE) can significantly impact quality of life. This burden extends…
  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology